natgillin/translations-raw huggingface dataset:
wherein the group c consists of: halogen atoms, hydroxyl, carboxyl, linear and branched alkyl, hydroxyalkyl, haloalkyl, alkylthio, alkenyl, and alkynyl groups; linear and branched alkoxyl groups; linear and branched thioalkyl groups; hydroxycarbonylalkyl; alkylcarbonyl; alkoxycarbonylalkyl; alkoxycarbonyl; trifluoromethyl; trifluoromethoxyl; -CN; -NO2; alkylsulphonyl groups optionally in the sulphoxide or sulphone forms; wherein any alkyl component has from 1 to 6 carbon atoms, and any alkenyl or alkynyl components have from 2 to 6 carbon atoms, and wherein, when there is more than one substituent, then each said substituent is the same or different, 
alkoksikarbonil; trifluorometil; trifluorometoksil; -CN; -NO2; alkilsulfonilne skupine proizvoljno u sulfoksidnom ili sulfonskom obliku; pri čemu svaka alkilna komponenta ima od 1 do 6 atoma ugljika, i svaka alkenilna ili alkinilna komponenta ima od 2 do 6 atoma ugljika, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit,
The orally dispersing tablet of any one of claims 1-3, further comprising an adhesive agent, wherein the adhesive agent is selected from the group consisting of sucrose aluminum sulfate complex, chitosan and derivatives thereof, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, cross-linked or uncross-linked polyacrylates, cross-linked polyarylates, acidic cross-linked or uncross-linked polyacrylates, polyacrylic acid homopolymers or copolymers, aminoalkyl methacrylate copolymers, methacrylic acid/methylmethacrylate copolymer, alkylacrylate/alkylmethacrylate copolymers, ammoniomethacrylate copolymers, carbomer homopolymers or copolymers, hydrophilic polysaccharide gums, maltodextrins, cross-linked alginate gum gels, polycarboxylated vinyl polymers, pectins, xanthan gums, alginic acid, modified alginic acids, and combinations thereof. 
ODT sukladno patentnom zahtjevu 1 ili 2, koja nadalje sadržava adhezivno sredstvo, pri čemu je adheziv odabran iz skupine koju čine saharoza aluminij sulfatni kompleks, hitosan i njegovi derivati, polivinilpirolidon, metilceluloza, natrij karboksimetilceluloza, hidroksipropil celuloza, umreženi ili neumreženi poliakrilat, umreženi poliarilata, kiselih umreženih ili neumreženih poliakrilata, homopolimeri ili kopolimeri poliakrilna kiselina, aminoalkil metakrilatni kopolimeri, kopolimeri metakrilne kiseline/metilmetakrilata, kopolimeri alkilakrilat/alkilmetakrilat, amoniometakrilatni kopolimeri, karbomerni homopolimeri ili kopolimeri, hidrofilni polisaharidi guma, maltodekstrini, umreženi alginatni gelovi od gume, polikarboksilirani vinilni polimeri, pektini, ksantanske gume, alginska kiselina, modificirana alginska kiselina ili njihove kombinacije.
A composition according to claim 5 comprising an ionizable drug, a crystallization inhibitor and a pH modifier, said composition providing a measurable improvement in dissolution rate of the ionizable drug, for use in the treatment of disease in a patient. A composition according to claim 5 comprising 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, a crystallization inhibitor and a pH modifier, said composition providing a measurable improvement in dissolution rate of the ionizable drug, for use in the treatment of disease in a patient. 
Uporaba 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-il)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli, inhibitora kristalizacije izabranog iz skupine koja obuhvaća hidroksipropilmetilcelulozu, polivinilpirolidon i hidroksipropilcelulozu te modifikatora pH za proizvodnju smjese, naznačena time, da ima mjerljivo poboljšan stupanj otapanja 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-il)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli za liječenje bolesti kod bolesnika kojemu će se dati ta smjesa.
isolating the compound of the Formula X by: 
Datum objave europske prijave patenta:
Use or HfO2 nanoparticles or HfO2 nanoparticles' aggregates for use according to claim 13, wherein said malignant cells are cells from a tumor selected in the group consisting of a haematological tumor and a solid tumor. 
Uporaba prema zahtjevu 12, gdje su te maligne stanice iz tumora odabranog iz skupine koju čine hematološki tumor i solidni tumor.
is selected from H, methyl, chloro and fluoro; 
R' je odabran od sljedećih: H, metil, kloro i fluoro;
a contiguous sequence of the human X light chain locus that spans from hVλ3-12 through hVλ3-1; 
graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-12 do hVλ3-1;
a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenytoin, amino(diphenylhydantoin) valeric acid, mephenytoin, fosphenytoin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, Y-aminobutyric acid, progabide, tiagabine, and the physiologically acceptable salts thereof. 
drugi farmakološki aktivni sastojak koji je antikonvulziv koji se bira iz skupine koju čine retigabin, lamotrigin, lakosamid, levetiracetam, karbamazepin, sultiam, fenacemid, felbamat, topiramat, feneturid, brivaracetam, selektracetam, zonisamid, stiripentol, beklamid, meksiletin, ralfinamid, metilfenobarbital, fenobarbital, primidon, barbeksaklon, metarbital, etotoin, fenitoin, amino(difenilhidantoin) valerijanska kiselina, mefenitoin, fosfenitoin, parametadion, trimetadion, etadion, etosuksimid, fensuksimid, mesuksimid, klonazepam, lorazepam, diazepam, klobazam, okskarbazepin, eslikarbazepin, rufinamid, valproična kiselina, valpromid, Y-aminomaslačna kiselina, progabid, tiagabin, te njihove fiziološki prihvatljive soli.
The inner part and/or the first and second outer parts may comprise means adapted to engage the element by means of snap-locks or other locks. 
Unutarnji dio i/ili prvi i drugi vanjski dijelovi mogu sadržavati sredstva koja su prilagođena da zahvaćaju element pomoću blokiranja sa skočnim mehanizmom ili pomoću neke druge blokade.
The solvent was removed by evaporation under reduced pressure. 
Otapalo se ukloni uparvanjem pri sniženom tlaku.
The stereoregular diblock polybutadiene according to any of the previous claims, wherein in said stereoregular diblock polybutadiene, the 1,4- cis /1,2 molar ratio ranges from 15:85 to 80:20. 
Stereoregularni diblok polibutadien u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u navedenom stereoregularnom diblok polibutadienu molarni omjer 1,4-cis/1,2 kreće od 15:85 do 80:20.
to 0.15 % (w/w) pimobendan, a pharmaceutical acceptable salt, derivative, metabolite or pro-drug thereof; 
pimobendan ili njegova farmaceutski prihvatljiva sol od 0,005 do 0,15% (masa/volumen);
inhibition of metastasis of a cell expressing CLDN6. The anti-CLDN6 antibody of claim 1, which exhibits one or more immune effector functions against a cell carrying CLDN6 in its native conformation. The anti-CLDN6 antibody of claim 11, wherein the one or more immune effector functions are selected from the group consisting of complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), induction of apoptosis, and inhibition of proliferation. 
Antitijelo suglasno bilo kojem od zahtjeva 1-7, koje pokazuje jednu ili više imunskih efektorskih funkcija usmjerenih prema stanicama koje pokazuju CLDNE6 u njegovoj nativnoj formi, naznačeno time da je jedna ili više efektorskih funkcija poželjno izabrana iz grupe koji čine citotoksičnost zavisna od komplementa (CDC), citotoksičnost posredovana antitijelima (ADCC), indukcija apoptoze i mhibicija proliferacije, a poželjno je da su efektorske funkcije ADCC i/ili CDC.
A process for cleaving a post-translational modification group, wherein a glycoprotein and/or a glycopeptide which are a test substance as well as the labeling agent according to any one of Claims 1-6 are dissolved or dispersed in a solvent and heat is applied under a basic condition, whereby the post-translational modification group from a serine residue and/or a threonine residue in the test substance is selectively cleaved and labeled. 
Postupak za cijepanje post-translacijske modifikacijske skupine iz serinskog ostatka i/ili treoninskog ostatka kod post-translacijski modificiranog glikoproteina i/ili glikopeptida, pri čemu su glikoprotein i/ili glikopeptid koji je ispitivana tvar kao i sredstvo za označavanje otopljeni ili dispergirani u otapalu i toplina se primjenjuje pod bazičnim uvjetima, pri čemu se post-translacijska modifikacijska skupina iz serinskog ostatka i/ili treoninskog ostatka u ispitnoj tvari selektivno cijepa i označava, pri čemu sredstvo za označavanje, kao aktivni sastojak, sadrži barem derivat pirazolona i pri čemu post-translacijska modifikacijska skupina je O-glikan.
A composition for use according to any preceding claim wherein the skeletal metastasis or bone metastasis results from prostate cancer. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili 2 za primjenu u inicijalnoj dozi degareliks od 160 do 320 mg;
The method according to any one of the preceding claims, wherein the number of oil droplets having a size of >1.2 µm in the first emulsion is 5 x 1011 /ml or less. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u prvoj emulziji je 5 x 10"! /ml ili manje.
and pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof. 
i njegove farmaceutski prihvatljive soli, hidrati, N-oksidi ili solvati.
It thus can slide back a forth between stops. 
On se dakle može klizno odmaknuti unatrag iz krajnjeg položaja.
deprotecting the compound of Formula L to give a compound of Formula LI; 
R-a j. = skidanje zaštite sa spoja Formule L, čime se dobiva spoj Formule LI:
separating the trans-(−)-A9-tetrahydrocannabinol and the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
(b) separaciju trans-(-)-A*-tetrahidrokanabinola i trans-(+)-A?-tetrahidrokanabinola od alkoholno-kaustične faze; i
a viscosimeter comprising a calibrated tube (6) working by measurement of a pressure drop in the calibrated tube at a constant rate of flow; the viscosimeter including: 
viskozimetar koji sadrži kalibriranu cijev (6) koji djeluje mjerenjem pada tlaka pada tlaka u kalibriranoj cijevi kod konstantnog protoka, te viskozimetar sadrži:
in step d), the aqueous suspension is exposed to a pressure of from 200 to 500 mbar, and wherein 
u koraku d), vodena suspenzija podvrgava se tlaku od 200 do 500 mbara, te gdje
The nonwoven fabric according to claim 1, wherein exterior surfaces of the bonded portions are recessed relative to exterior surfaces of the unbonded portions at each of the opposite faces of the nonwoven fabric. 
Netkani materijal prema zahtjevu 1, naznačen time da su vanjske površine spojenih dijelova udubljene u odnosu na vanjske površine nespojenih dijelova na svakom od nasuprotnih lica netkanog materijala.
Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or salts and/or hydrates and/or solvates and/or polymorphs thereof for use in a method of treating schizophrenia with the therapeutically effective amount of 1.5, 3.0 or 4.5 mg/day. 
Spoj, naznačen time, da je to trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin i/ili njegove soli i/ili njegovi hidrati i/ili solvati i/ili polimorfi, koji su za uporabu u postupku liječenja shizofrenije s terapeutski učinkovitom količinom od 1,5; 3,0 ili 4,5 mg na dan.
Thus, it is within the scope of the present invention to use ancillary groups such as, for example, small repeating units of ethylene glycols, alcohols, polyols, (e.g., glycerin, glycerol propoxylate, etc.) carboxylates (e.g., small repeating units of glutamic acid, acrylic acid, etc.), amines (e.g., tetraethylenepentamine), and the like to enhance the water solubility and/or hydrophilicity of the carbohydrate rapamycin derivatives of this invention. 
Tako je unutar opsega ovog izuma upotrebljavati pomoćne grupe kao što su, na primjer, male ponavljajuće jedinice etilen-glikola, alkohola, poliola (npr. glicerin, glicerol-propoksilat itd.), karboksilata (npr. male ponavljajuće jedinice glutaminske kiseline, akrilne kiseline, itd.), amina (npr. tetraetilenpentamin) i slično, kako bi se povećala topljivost u vodi i/ili hidrofilnost ugljikohidratnog derivata rapamicina ovog izuma.
Method for producing a preform in an injection moulding mould according to one of the claims 1 to 22, wherein a predetermined quantity of a primary, respectively tertiary synthetic material (PM, TM) is injected in a hollow mould space under a relatively high pressure p and temperature T, characterised in that a predetermined quantity of a secondary material (SM) is further fed in the hollow mould space under conditions of pressure and/or temperature which are substantially lower than said primary and tertiary injection pressure p, resp. temperature T, wherein said conditions of temperature for the feeding of secondary material (SM) are substantially at room temperature. 
Postupak proizvodnje predoblika, prema jednom od zahtjeva 1 do 22, u kalupu za oblikovanje uštrcavanjem, gdje se unaprijed određena količina primarnog, odnosno tercijarnog sintetskog materijala (PM, TM) uštrcava (injicira) u šuplji prostor kalupa pod relativno visokim tlakom p i temperaturom T, naznačen time što se unaprijed određena količina sekundarnog materijala (SM) dalje unosi šuplji prostor kalupa pod uvjetima tlaka i/ili temperature koji su HR P20110221 T1 bitno niži od navedenog tlaka uštrcavanja p, odnosno temperature T za primarni i tercijarni materijal, pri čemu su uvjeti temperature za unos sekundarnog materijala (SM) u biti sobna temperatura.
The transdermal delivery device of claim 14, further comprising an adhesive layer adjacent to, and in contact with, the matrix layer and permeable to the therapeutically active agent. 
Sredstvo za transdermalno davanje prema zahtjevu 14, naznačeno time da nadalje sadrži adhezivni sloj koji se nalazi pored i koji je u kontaktu s matričnim slojem i koji je propustan za terapeutski aktivni agens.
The compound of formula (I') of claim 5 for its use according to claim 5, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (T') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, gdje u formuli (T), R' je atom vodika, i R* je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa; ravna ili razgranata C;- Cs alkoksi grupa; ili ravna ili razgranata C;-Cz tioalkil grupa.
measuring the soluble molecule in a second biological sample, wherein the second biological sample has been obtained from the individual within thirty-one days after administration of the alpha-4 integrin inhibitor; 
mjerenje topive molekule u drugom biološkom uzorku, pri čemu je drugi biološki uzorak odabran iz skupine koja se sastoji od krvi, seruma i plazme i bio je dobiven od pojedinca u roku od trideset jednog dana nakon primjene alfa-4 integrinskog inhibitora;
The particle size of the drug substance influences biopharmaceutical properties of the drug product. 
Veličina čestica ljekovite tvari utječe na biofarmaceutska svojstva ljekovitog produkta.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1 to 16, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 16, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 °C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) vezano uz deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
The fractions were collected, pooled, concentrated and dried in a vacuum oven at 50° C. to give product of Formula 44. 
Frakcije su bile sakupljene, spojene, koncentrirane i osušene u vakuumskoj pećnici pri 50*C da bi se dobio produkt formule 44.
(a1) an antigen-binding site comprising an H chain variable region having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 35; 
(a1) mjesto vezanja antigena koje obuhvaća aminokiselinsku sekvencu varijabilnog područja H-lanca od SEQ ID NO: 35 (varijabilno područje H-lanca od Q1);
In all cases, symptoms however resolved rapidly. The use of an influenza virus or antigenic preparation thereof and an oil-in-water emulsion adjuvant in the preparation of an immunogenic composition for vaccination of human elderly aged 65 years old and over against influenza, wherein said oil-in-water emulsion comprises a metabolisable oil, alpha-tocopherol and an emulsifying agent. 
Upotreba virusa influence ili njegovog antigenskog pripravka i emulzije ulja u vodi kao adjuvansa u pripravi imunogenog pripravka za cijepljenje čovjeka starijeg od 65 godina i više protiv influence, naznačena time što navedena emulzija ulja u vodi sadrži ulje koje se može metabolizirati, a-tokoferol i emulgator.
The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion. 
Farmaceutski pripravak prema zahtjevu 9, naznačen time da je farmaceutski pripravak formuliran za davanje: oralno, = intraadipozno, = intraarterijski, = intraartikularno, = intrakranijalno, = intradermalno, = intralezionalno, intramuskularno, intranazalno, intraokularno, intraperikardijalno, intraperitonealno, intrapleuralno, intraprostatski, intrarektalno, intratekalno, intratrahealno, intratumoralno, intraumbilikalno, intravaginalno, intravenozno, intravezikularno, intravitrealno, liposomalno, lokalno, mukozalno, parenteralno, rektalno, subkonjunktivno, subkutano, sublingvalno, topikalno, transbukalno, transdermalno, vaginalno, u kremi, u lipidnim pripravcima, putem katetera, putem ispiranja, kontinuiranom infuzijom, infuzijom, inhalacijom, putem injekcije, putem lokalne isporuke, ili putem lokalizirane perfuzije.
A composition as claimed in Claim 1, wherein the cancer is a member of the group consisting of leukemia, breast cancer, ovarian cancer, lung cancer, bladder cancer, prostate cancer, pancreatic cancer, and cervical cancer. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što rak je iz skupine koju čine leukemija, rak dojke, rak jajnika, rak pluća, rak mokraćnog mjehura, rak prostate, rak gušterače i rak vrata maternice.
The immunoresponsive cell of claim 17, wherein the CAR is P28z. The immunoresponsive cell of claim 1, wherein the immunoresponsive cell is a T cell, the cytokine comprises an IL-12, and the antigen is expressed by a solid tumor selected from the group consisting of prostate cancer, colon cancer, breast cancer, ovarian cancer, and glioblastoma. 
T-stanica za uporabu prema zahtjevu 19 ili farmaceutski pripravak za uporabu prema zahtjevu 20 ili 21, naznačen time da: neoplazija je odabrana iz skupine koju čine rak prostate, rak debelog crijeva, raka dojke, i glioblastom; i/ili tumorski antigen je odabran iz skupine koju čine membranski antigen specifičan za prostatu (PSMA), CD19, NY-ESO-1, WT-1, hTERT, i mezotelin.
An apparatus as claimed in claim 15, wherein the waste extraction machine comprises non-circular rotors spaced apart along a sequence of axles, and wherein the rotors rotate to propel the wood pieces along the machine from axle to axle, and also act to bounce the wood pieces up and down due to the non-circular shape. 
Uređaj u skladu s patentnim zahtjevom 10 ili 11, naznačen time što stroj za izvlačenje otpada (2) ima nekružne rotore (17), međusobno razmaknute po nizu osovina (16), te što se rotori (17) vrte kako bi slali komade drva kroz stroj od osovine do osovine, koji također tako djeluju da komadi drva poskakuju gore i dolje zbog nekružnog oblika.
The method as claimed in claim 1, wherein the binder is a blank ink comprising a liquid substance that is applied by a digital drop application head. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što je tekuće vezivo bezbojna tinta (11) koja sadrži tekuću supstancu koja se primjenjuje pomoću digitalne aplikacijske glave (30').
A capsule according to any one of claims 1-3, wherein the at least one projection (28.i; 107; 117; 127; 137) is provided on separate regions along a periphery of the capsule. 
Kapsula prema jednom od patentnih zahtjeva 1-3, pri čemu najmanje jedan ispupčeni dio (127) postoji na odvojenim područjima duž periferije kapsule (110).
The present invention additionally relates to the binding molecules mentioned above, wherein the first binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of: 
Vezujuća molekula prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što prva vezujuća domena sadrži VH regiju koja sadrži CDR-H1, CDR-H2 i CDR-H3 i VL regiju koja sadrži CDR-L1, CDR-L2 i CDR-L3 odabrane iz skupine koja sadrži:
#31” (as per manufacturer instructions). 
#31" (po uputama proizvođača).
The method according to claim 1, wherein the sealing material is selected from the group consisting of fibers, paper, cotton, viscous paste, and foam. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, u kojemu je materijal za brtvljenje (8) odabran iz skupine koja sadržava vlakna, papir, pamuk, viskoznu pastu, pjenu.